Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019050521) DOSING REGIMENS OF BI-SPECIFIC CD123 X CD3 DIABODIES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/050521 International Application No.: PCT/US2017/050471
Publication Date: 14.03.2019 International Filing Date: 07.09.2017
IPC:
A01N 65/00 (2006.01)
A HUMAN NECESSITIES
01
AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
N
PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
65
Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
Applicants:
MACROGENICS, INC. [US/US]; 9704 Medical Center Drive Rockville, MD 20850, US
Inventors:
WIGGINTON, Jon, Marc; US
ALDERSON, Ralph, Froman; US
LECHLEIDER, Robert, Joseph; US
Agent:
AUERBACH, Jeffrey, I.; US
SCHROT, William, C.; US
Priority Data:
Title (EN) DOSING REGIMENS OF BI-SPECIFIC CD123 X CD3 DIABODIES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
(FR) SCHÉMAS POSOLOGIQUES DE DIACORPS BISPÉCIFIQUES CD123 X CD3 DANS LE TRAITEMENT DE MALIGNITÉS HÉMATOLOGIQUES
Abstract:
(EN) The present invention is directed to a dosing regimen for administering a CD123 x CD3 bi-specific monovalent diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such a regimen for the sequence-optimized CD 123 x CD3 bi-specific monovalent diabody "DART-A," that is capable of simultaneous binding to CD 123 and CD3.
(FR) La présente invention concerne un schéma posologique d’administration d’un diacorps monovalent bispécifique CD123 x CD3 à des patients présentant une malignité hématologique telle qu’une leucémie myéloïde aiguë (AML) ou un syndrome myélodysplasique (MDS). L’invention concerne particulièrement l’utilisation d’un tel schéma pour le diacorps monovalent bispécifique CD123 x CD3 à séquence optimisée "DART-A," qui est capable de liaison simultanée à CD123 et CD3.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)